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Abstract
Background: Atopic dermatitis (eczema) is a type of inflammation of the skin, which presents with itchy, red,
swollen, and cracked skin. The high global incidence of atopic dermatitis makes it one of the major skin diseases
threatening public health. Sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) act as pro-
inflammatory mediators, as an angiogenesis factor and a mitogen in skin fibroblasts, respectively, both of which are
important biological responses to atopic dermatitis. The SPC level is known to be elevated in atopic dermatitis,
resulting from abnormal expression of sphingomyelin (SM) deacylase, accompanied by a deficiency in ceramide.
Also, S1P and its receptor, sphingosine-1-phosphate receptor 1 (S1P1) are important targets in treating atopic
dermatitis.
Results: In this study, we found a novel antagonist of SPC and S1P1, KRO-105714, by screening 10,000 compounds.
To screen the compounds, we used an SPC-induced cell proliferation assay based on a high-throughput screening
(HTS) system and a human S1P1 protein-based [35S]-GTPγS binding assay. In addition, we confirmed the inhibitory
effects of KRO-105714 on atopic dermatitis through related cell-based assays, including a tube formation assay, a
cell migration assay, and an ELISA assay on inflammatory cytokines. Finally, we confirmed that KRO-105714 alleviates
atopic dermatitis symptoms in a series of mouse models.
Conclusions: Taken together, our data suggest that SPC and S1P1 antagonist KRO-105714 has the potential to
alleviate atopic dermatitis.
Keywords: Sphingosylphosphorylcholine, Sphingosine-1-phosphate receptor 1, Antagonist, Anti-inflammatory,
Atopic dermatitis, High-throughput screening
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Introduction
Atopic dermatitis (eczema) is a common inflammatory
skin disease; up to 245 million people globally experi-
enced atopic dermatitis in 2015 [1]. Thus, this disease is
one of the major skin diseases threatening public health.
Sphingosylphosphorylcholine (SPC) and sphingosine-1-
phosphate (S1P) are known as important targets for
atopic dermatitis. SPC and S1P are sphingomyelin me-
tabolites generated from sphingomyelin (SM), which is
one of the major components in the plasma membranes
of eukaryotic cells and regulates cholesterol homeostasis.
The sphingomyelin metabolites, S1P, ceramide, sphingo-
sine, and diacylglycerol have important functions in vari-
ous cellular processes, including cell apoptosis, aging,
differentiation, and development [2–5]. SM deacylase
hydrolyzes SM to yield SPC rather than the ceramides
produced by sphingomyelinase (SMase). Abnormally
high expression of SM deacylase in the epidermis of
patients with atopic dermatitis causes a ceramide defi-
ciency resulting in atopic dry skin [6, 7]. Okamoto et al.
reported that accumulation of SPC in the stratum cor-
neum of patients with atopic dermatitis is related to de-
creasing ceramide levels in the stratum corneum [8].
SPC was shown to rapidly increase intracellular free cal-
cium ([Ca2+]i) and promote a rapid activation of
mitogen-activated protein kinase (MAPK) in several dif-
ferent cell types [9]. Because a rise in [Ca2+] appears to
be an initial and common response to stimulation of
proliferation and differentiation in a variety of cell types,
SPC is a potent mitogen that promotes DNA synthesis
and cellular proliferation to a greater extent than other
known growth factors [10, 11]. SPC plays an important
role in the inflammatory process by increasing the gen-
eration of pro-inflammatory cytokines, such as tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and
enhancing wound healing through the release of con-
nective tissue growth factor and adhesion molecules
[12–14]. SPC stimulates monocyte chemotactic protein-
1 (MCP-1) production through p38 MAPK/JNK- and
nuclear factor-κB (NF-κB)/activator protein 1 (AP-1)-
dependent pathways in endothelial cells [15]. MCP-1/
chemokine (C-C motif) ligand-2 (CCL-2) is a key inflam-
matory mediator involved in autoimmune pathogenesis
[16]. Like MCP-1, SPC is generally thought to be a dele-
terious factor in skin pathology [17]. For example, SPC
elevates intracellular calcium levels and the level of re-
active oxygen species in endothelial cells, thereby enhan-
cing their migration [18, 19]. Furthermore, SPC reduced
IL-1β and prostaglandin E2 (PGE2) formation through
the transforming growth factor (TGF)-β receptor in
renal mesangial cells, which contrasts with its pro-
inflammatory actions in fibroblasts [20].
Although several studies have attempted to identify a re-
ceptor for SPC, no high affinity SPC-specific membrane
receptor has been identified, unlike sphingosine 1-phosphate
(S1P) and lysophosphatidic acid (LPA) [21]. Shortly after the
characterization of ovarian cancer G-protein-coupled recep-
tor 1 (ORG1) and G-protein-coupled receptor 4 (GPR4) as
high affinity SPC receptors, evidence was published showing
that both of these receptors act as proton-sensing G-protein-
coupled receptors (GPCRs) in response to extracellular pH
change [22]. Further studies have indicated that the expres-
sion of GPR4 reduces extracellular signal-regulated kinase
(ERK) activation in a ligand-independent manner [23] and
causes SPC to antagonize the pH-induced receptor signaling
[24]. Subsequent studies failed to reproduce important fea-
tures of the original reports characterizing ORG1 and GPR4
as high affinity SPC receptors, and the initial papers were
retracted [25]. Some studies showed that G2A is a proton-
sensing GPCR antagonized by lysophosphatidylcholine
(LPC) [26]. In addition, studies showed that the G2A ligand
independently stimulates the accumulation of inositol phos-
phates and induces apoptosis within the cell [27]. Despite
lacking a defined extracellular binding site, a number of stud-
ies indicated that SPC-induced effects can occur exclusively
via plasma membrane receptors for S1P or LPA [28, 29].
In this study, we found the novel antagonist against
both SPC and S1P1 to act as a potential therapeutic
agent in treating atopic dermatitis. We performed an
SPC-induced proliferation assay using a combinatorial li-
brary of 10,000 compounds and found an active com-
pound; KRO-105714 (2,4,5-trisubstituted-1,3-thiazole
derivative). We were able to confirm it as a potent S1P1
inhibitor [30]. To demonstrate the therapeutic effects of
KRO-105714 on atopic dermatitis, we performed a series
of atopic dermatitis-related cell-based assays, including
an angiogenesis assay, a cell migration assay and an in-
flammation cytokine assay. In addition, we confirmed
that KRO-105714 alleviated atopic dermatitis symptoms
in the mouse models. Taken together, we suggest KRO-
105714, an antagonist of SPC and S1P1, as a potential
therapeutic agent against atopic dermatitis.
Results
SPC-antagonistic effect of a novel compound, KRO-
105714 against SPC-induced cell proliferation
In this study, we screened inhibitors of cell proliferation
based on SPC-induced cell conditions from a 10,000-
compound synthesized by combinatorial methods at the
Korea Research Institute of Chemical Technology, using
an HTS system. As a result, we acquired 501 compounds
that have an inhibitory effect greater than 88% at 2.5 μM
as primary hits. The compound (KRO-105714), shown
in Fig. 1a, was the most potent compound in SPC-
induced cell inhibitory effect; its chemical structure was
identified as 2,4,5-trisubstituted-1,3-thiazole. We then
examined the effects of KRO-105714 on cell viability.
Figure 1b shows KRO-105714 as a potent inhibitor of
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Fig. 1 a Chemical structure of KRO-105714. b The inhibitory effects of KRO-105714 on the proliferation of SPC-induced NIH3T3 cells. The cells were
exposed to various concentrations of KRO-105714 for 30min, and then treated with 10 μM of SPC for 24 h. Then inhibition rates were calculated by
comparing the corresponding viability values of the control group. Each sample was assayed in triplicate
Fig. 2 a Antagonistic effects of KRO-105714 by SPC (a: [35S]-GTPγS binding assay, b: Migration assay). The HEK-293 cells stably expressing hS1P1
were homogenized with assay buffer and pre-incubated with GTP-binding buffer in the presence or absence of 0.8 nM, 4 nM, 20 nM, 100 nM, 500
nM and 2.5 μM KRO-105714 with 10 μM SPC for 30 min. 1200 Ci/mmol; 0.1 nM [35S]-GTPγS was loaded and incubated for 30 min. Nonspecific
binding was determined in the presence of 30 μM GTPγS. Each dose of the test compound was assayed in triplicate on pooled samples. b
Migration assays were performed in Transwell 96-well chambers. SPC (10 μM) was placed in the lower well. HUVECs were harvested and treated
with test compounds for 30 min before seeding. The cell suspension was loaded into the upper well. Cells were allowed to migrate for 4 h in a
humidified chamber. The cells were fixed and stained with hematoxylin and eosin. Cell migration was quantified by counting the cells that
attached to the lower surface of the filter using an optical microscope at X200 magnification. Fifteen fields were counted for each assay. Each
dose of the test compound was assayed in triplicate on pooled samples. c Tube formation effects of KRO-105714 in HUVECs. Representative
photographs of HUVEC tube formation induced by control (vehicle, 0.1% DMSO) (a), 10 μM of SPC (b), 10 μM of SPC, and 2.5 μM of KRO-105714
are shown from three different independent experiments
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SPC-induced cell proliferation in NIH3T3 cells. This
compound was first reported as an SPC antagonist in
this study. Before confirming the SPC-antagonistic
effects of KRO-105714, we synthesized KRO-105714 and
compared our analytical data with those in the Korean
pat. No. 1051078 and U.S. pat. No. 7915405 [30]. Results
of 1H NMR and 13C NMR of our synthesized KRO-
105714 compound were shown in Additional file 1:
Figure S1. LC-MS (ESI) and HRMS (ESI) were calculated
for KRO-105714 (Additional file 1: Figure S2). The SPC
antagonist capacity (IC50 = 5.6 nM) in Fig. 1b was dem-
onstrated using newly synthesized KRO-105714 as men-
tioned above.
Antagonistic activity of KRO-105714 against S1P1
receptor
We determined whether KRO-105714 affects interac-
tions between SPC and S1P1 receptor. Figure 2a showed
that, as expected, treatment with KRO-105714 signifi-
cantly inhibited the binding of S1P1 and GTP. From the
human S1P1-based [35S]-GTPγS binding assay, KRO-
105714 showed dose-dependent inhibition of GTP bind-
ing in lysates of HEK-293 cells expressing S1P1. The
IC50 value of KRO-105714 in the [
35S]-GTPγS binding
assay was 79.2 nM (Fig. 2a). These results suggest that
KRO-105714 acts as an antagonist of S1P1.
Inhibitory effect of KRO-105714 on SPC-induced
migration in endothelial cells and SPC-induced
endothelial tube formation
Increased angiogenesis is one of the most critical charac-
teristics in atopic dermatitis. SPC is also a well-known
material for its pro-angiogenetic capacity. Thus, we won-
dered whether KRO-105714 had an inhibitory effect on
SPC-mediated angiogenesis and examined migration to
investigate the effect of KRO-105714 on SPC-induced
endothelial cell migration. First, we found that SPC-
stimulated chemotactic migration of HUVECs was dose-
dependently inhibited by KRO-105714, and the IC50 in
the migration assay was measured as 0.59 μM (Fig. 2b).
Then, we examined the anti-SPC effect of KRO-105714
on SPC-induced tube formation in HUVECs. Figure 2c
shows that 2.5 μM of KRO-105714 antagonized SPC-
induced tube formation (Fig. 2c).
Inhibitory effects of KRO-105714 on SPC-induced Th2
cytokine production
To evaluate the effectiveness of KRO-105714 on pro-
inflammatory chemokine and cytokine production from
macrophages in an SPC-induced inflammatory condi-
tion, we treated the RAW 264.7 cells and human PBMCs
with KRO-105714 in the presence or absence of SPC
(Fig. 3). Cell supernatant was collected and analyzed
using ELISA kits. As expected, KRO-105714 inhibited
SPC-induced MCP-1 release in RAW 264.7 cells (Fig.
3a). Also, we investigated the inhibitory effects of KRO-
105714 on Th2 cytokines: IL-4 and IL-5, which are im-
portant for allergic-responses. Human PBMCs treated
with KRO-105714 (1 and 10 μM) were exposed to PHA
with/without SPC, to induce allergic-response conditions
for 24 h or 72 h. Then, the supernatant was collected for
measurement of the cytokines. As shown in Fig. 3, we
confirmed that KRO-105714 suppressed IL-4 and IL-5,
triggered by SPC in the presence of PHA in PBMCs. As a
result, KRO-105714 was found to have an antagonistic ef-
fect on the SPC-induced production of Th2 cytokines IL-4
and IL-5 from PBMCs in a dose-dependent manner. Also,
ICAM-1, an adhesion molecule known to be induced in
atopic dermatitis patients than normal individuals, were
down-regulated by KRO-105714 compound in SPC and
PHA co-treated PBMCs (Fig. 3d) [31].
Effects of KRO-105714 in multiple in vivo atopic
dermatitis models
In vivo efficacy of KRO-105714 was determined in TPA-
induced atopic dermatitis ear model. Hydrocortisone
(HC), a potent topical corticosteroid, was chosen as the
reference compound [32]. As shown in Fig. 4a, KRO-
105714 reduced ear weights of TPA-induced atopic
dermatitis mice. TPA treatment increased ear thickness
in this mouse model and KRO-105714 applied on the
ear skin significantly reduced ear swelling symptoms and
the reduction efficacy was dose-dependent. 0.5% of
KRO-105714 exhibited a similar anti-inflammatory effect
to 0.5% HC. KRO-105714 also showed a therapeutic ef-
fect in an oxazolone-induced mouse model, although the
efficacy was weaker than HC (Fig. 4b). To understand
the therapeutic mechanism associated with KRO-105714
in these dermatitis models, we analyzed MPO and EPO
activities, which are well-known for their critical roles in
dermatitis. As a result, KRO-105714 significantly re-
duced MPO activity in TPA-induced dermatitis tissues.
Specifically, KRO-105714 showed an inhibition rate of
about 80% when applied at 0.5 and 1.0% in the TPA
model (Fig. 4c). In addition, KRO-105714 inhibited the
activity of EPO at about 40% in the oxazolone-induced
mouse model (Fig. 4d). Furthermore, to investigate the
effect of KRO-105714 on scratching behavior, which is
one of critical indicates for atopic dermatitis, we used
the DNCB-induced atopic dermatitis mouse model and
measured itch-scratch response (ISR). To evaluate the
effectiveness of KRO-105714 on ISR of the DNCB-
induced atopic dermatitis-like skin lesions, the mice
were treated with 1% KRO-105714 and 0.2% DNCB daily
for 4 days. As shown in Fig. 5a, oral administration of
KRO-105714 reduced SPC-induced ISR in a dose-
dependent manner compared to the untreated group in
the DNCB-induced atopic dermatitis mice. Also,
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repeated DNCB application significantly increased mul-
tiple atopic dermatitis symptoms, such as hemorrhage
edema, scarring, dryness, and erosion in NC/Nga mice
(Fig. 5b). Only DNCB treated mice showed severe
hemorrhage edema, scarring, dryness, and erosion symp-
toms. However, KRO-105714 at 1% with DNCB treated
mice showed much less hemorrhage edema, scarring, dry-
ness, and erosion symptoms compared to only DNCB
treated mice. Also, the alleviating effect on atopic derma-
titis mice by KRO-105714 was a similar level to the HC-
treated with DNCB group.
Discussion
SPC and S1P/S1P1 are known as important players in the
pathological pathways of atopic dermatitis. In previous
reports [6–8], the concentration of SPC is increased in
atopic dermatitis lesions of clinical patients and a con-
comitant decrease in ceramide levels is regarded as a
pathogenic factor, because Sphingomyelin (SM) is metab-
olized to ceramide by sphingomyelinase (SMase) or alter-
natively metabolized SPC by SM deacylase [33, 34]. SPC
functions as a signal transducer in various cellular pro-
cesses, such as proliferation, differentiation, migration and
apoptosis, and works as an important mediator of atopic
dermatitis [2, 10]. Moreover, SPC is known as a stimula-
tion factor for multiple immune cells, such as monocytes
and macrophages, to amplify inflammation in many in-
flammatory diseases [34]. Thus, the level of SPC in skin
inflammatory lesions might be an indicator of atopic
dermatitis. However, so far, no SPC receptor has been
Fig. 3 a Effects of KRO-105714 on chemokine levels in stimulator-induced RAW 264.7 cells. The RAW 264.7 cells were seeded in 96-well plates at
a density of 2 × 104 cells/well and pre-treated with various concentrations (1, 3, 10 μM) of KRO-105714 for 30 min and then treated with 10 μM of
SPC for 24 h. Expression levels of MCP-1 were measured using ELISA. Each dose of the test compound was assayed in triplicate and the assays
were repeated three times. Data are shown as mean ± standard deviation (SD). *P < 0.05, ** P < 0.01 and *** P < 0.001 is the significance level
compared to the SPC treated group. b-c Inhibitory effects of KRO-105714 on the expression of pro-inflammatory cytokines and adhesion molecule.
The cytokines used were PBMCs isolated from the blood of healthy individual donors. The human PBMCs were seeded in 96-well plates at a density of
5 × 105 cells/well and pre-treated with concentrations (1 and 10 μM) of KRO-105714 for 30min and then treated with 10 μM of SPC and 5 μg/ml of
PHA for 24 h (b) of 72 h (c). IL-4 (b), and IL-5 (c) levels were measured using ELISA. Each dose of the test compound was assayed in triplicate. ICAM-1
expression level of PBMCs (d) was measured using flow cytometry. MFI means “mean fluorescence intensity”. Data are shown as mean ± standard
deviation (SD). *P < 0.05, ** P < 0.01 and *** P < 0.001 versus compound-untreated cells (ANOVA multiple comparison)
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clearly identified. Thus, the use of an SPC antagonist is
the only method to block the SPC induced signal pathway.
Thus, our study, which focused on finding SPC antago-
nists, considered the importance of SPC in atopic
dermatitis pathology. In addition, S1P is metabolized from
SM and functions as a pro-inflammatory mediator and
angiogenesis factor, which are biological responses related
to atopic dermatitis [35, 36]. Thus, S1P or its receptor,
Fig. 4 Alleviated effects of skin inflammation in ear edema models (a, b: measurement of ear weight, c: myeloperoxidase assay, d: eosinophil assay).
KRO-105714 solution was applied to the ears of ICR mice twice in 15min and 6 h after application of TPA (a, c) or in 0 h and 6 h after application of
oxazolone (b, d). a, b After 24 h, a whole ear weight was measured using an electronic balance. Then, expression levels of MPO (c) or EPO (d) in ear
skin were analyzed. Data are shown as mean ± standard deviation (SD). NS: not significant; NS: not significant; *P < 0.05, ** P < 0.01 and *** P < 0.001
versus compound-untreated cells (ANOVA multiple comparison)
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S1P1 should also be therapeutic targets for atopic derma-
titis. Our SPC and S1P1 dual inhibitory compound, KRO-
105714 should therefore be a potent candidate molecule
for atopic dermatitis.
In this study, we identified KRO-105714 as an SPC
antagonist and inhibitor of the S1P receptor, S1P1, by
screening inhibitors from a 10,000-compound library
based on the SPC-induced cell proliferation and a hu-
man S1P1 protein-based [35S]-GTPγS binding assay.
KRO-105714 showed potent SPC inhibitory (IC50 =
5.6 nM) and antagonistic (IC50 = 79.2 nM) activities in
GTP binding assay (Fig. 2a and b). Increased angio-
genesis, fibrosis, and infiltration of immune cells are
critical characteristics of atopic dermatitis. In a previ-
ous report [37], researchers showed that SPC has
pathological vasculogenic and fibrogenic activities in
atopic dermatitis. Piao et al. explained that SPC can
induce endothelial cell sprouting in an in vitro angio-
genesis model and increased tube-like formation in an
in vivo wound healing model [38]. Based on those
previous reports, SPC’s pathological angiogenic power
is an important therapeutic target in atopic dermatitis.
Fig. 5 Effects of KRO-105714 treatment on itch-scratch response (ISR) and DNCB-induced atopic dermatitis in animal models. a itch-scratch
response (ISR) of evaluation of scratching behavior mouse model. To measure itch-related behavior induced by SPC, KRO-105714 was administered to
ICR mice (8 weeks, male, n = 5 per group) via oral administration of 1 and 10mg/kg KRO-105714 with the SPC application (100 nM/site), bouts of
scratching were counted for 30min. Data are shown as mean ± standard deviation (SD). *P < 0.05, and ** P < 0.01 versus mice with vehicle (n = 5)
(ANOVA multiple comparison). b Images of skin lesions from the groups of mice were taken on the last day of the experiment (a; Non-treated, b; 0.2%
DNCB, c; 0.2% DNCB/1% KRO-105714, d; 0.2% DNCB/1% hydrocortisone). Representative images from five different mice per group are shown
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As we expected, KRO-105714 showed a potent inhib-
ition on the SPC-induced HUVEC tube formation and
endothelial cell migration (IC50 = 0.59 μM) (Fig. 2c)
indicating KRO-105714 an anti-angiogenic compound.
Equally important is the cytokine blocking effect of
SPC in skin diseases, which has been suggested to
play a role in the inflammatory processes of the epi-
dermis through up-regulation of monocyte chemotac-
tic protein-1 (MCP-1) [6]. MCP-1 is a well-known
potent inflammatory chemokine which exacerbates in-
flammatory dermatitis by recruiting inflammatory
immune cells such as monocytes, macrophages, and
neutrophils [39]. Because MCP-1 is a potent chemo-
tactic factor that triggers the infiltration of mono-
cytes/macrophages into inflammatory sites [15],
expression of MCP-1 is an indicator for many
inflammation-associated pathological states, such as
dermatitis [6], rheumatoid arthritis, atherosclerosis
[40], diabetic nephropathy [39], lung inflammation
[40] and cancer [41]. It has been reported that the
administration of MCP-1 inhibitors inhibits macro-
phage accumulation into inflammatory lesions and
improves disease outcomes [42]. Based on these re-
ports, SPC should be a triggering factor to increase
expression of MCP-1 from mouse monocytes and hu-
man PBMCs to increase infiltration of immune cells.
Thus, the inhibitory effect of KRO-105714 on expres-
sion of MCP-1 would contribute in reducing inflam-
mation in the dermatitis lesions.
In atopic dermatitis, Th2 cytokines such as IL-4
and IL-5 are known to have an important function in
amplifying allergic inflammation in skin lesions [43].
In this study, we found that SPC strongly trigger se-
cretion of Th-2 cytokines (IL-4 and IL-5) relating to
allergic reactions from PBMCs (Fig. 3b and c). As
previously reported, IL-4 and IL-5 mediate the secre-
tion of IgE in B cells [44]. These previous studies
support the role of SPC as an allergic effector in
atopic dermatitis [6–8, 29]. Thus, we confirmed that
KRO-105714 inhibits an SPC-induced secretion of
Th-2 cytokines. Actually, this study is the first report
to show SPC co-treatment with PHA enhanced IL-4
and IL-5 induction from PBMCs. Because the role of
SPC in production of IL-4 and IL-5 is important to
understand allergic responses, this should be further
investigated to understand the underlying mecha-
nisms. For in vivo experiment, we still need to iden-
tify which is the proper animal model for this finding.
There is no previous report that SPC induced IL-4
and IL-5 in vivo model yet. Also, these allergic re-
sponse related that SPC induced Th2 cytokine pro-
duction should be further studied to clearly
understand the mechanism of KRO-105714 on SPC
related to atopic dermatitis.
Topical application of TPA and oxazolone is a valid
model to screen potential therapeutic agents for treat-
ment of inflammatory dermatitis [45, 46]. The measure-
ments of MPO activity confirm that KRO-105714 could
inhibit neutrophil level in inflammatory lesions of a
TPA-induced mouse model [47] (Fig. 4c). Increased in-
filtrated eosinophils in atopic dermatitis lesions is a well-
known feature of most patients with atopic dermatitis,
and T cell activation by antigen-presenting cells leads to
the production of Th2 cytokines that support eosinophil
functions [48]. As we discussed, reduction of MCP-1 ex-
pression levels by KRO-150714 might be the factor to
reduce MPO and EPO, because neutrophil and eosino-
phil also used the chemokine, MCP-1 [49]. Further study
is required to understand this MCP-1 related mechan-
ism for reduced MPO and EPO. In this study, to deter-
mine whether the confirmed activity of KRO-105714 on
anti-inflammation correlates in vivo in three different
mouse models, we performed repeated applications of
TPA and oxazolone to sensitize mice for induction of
atopic dermatitis associated symptoms. In both the TPA
and oxazolone induced dermatitis models, KRO-105714
reduced ear weights and MPO and EPO activity (Fig. 4).
Also, in a scratch behavior experiment using a DNCB-
induced dermatitis mouse model, KRO-105714 markedly
inhibited SPC-induced ISRs when orally administered to
mice (Fig. 5a and b). Similarly, KRO-105714 caused re-
covery in the atopic dermatitis symptoms such as
hemorrhage edema, scarring, dryness, and erosion from
DNCB-induced skin inflammatory response in NC/Nga
mice (Fig. 5c).
As we demonstrated, KRO-105714 showed potent
anti-allergic activity in both the in vitro and in vivo as-
says, implying its potential value as a novel therapeutic
for atopic dermatitis. For evaluation of KRO-105714 as a
drug candidate, we testified its important toxicities such
as hepatotoxicity (Additional file 1: Figure S3) and hERG
(Additional file 1: Table S1). After oral administration of
KRO-105714 compound (250 mg per kilogram of mouse
weight and 500mg per kilogram of mouse weight) did
not show any effect on alanine aminotransferase
(ALT) activity from blood plasma of mice (Additional
file 1: Figure S3). KRO-105714 did not inhibit
CYP450, indicating it had no drug-induced hepatotox-
icity (1A2: > 10 μM, 2C9: > 10 μM, 2C19: > 10 μM,
2D6: > 10 μM, 3A4: > 10 μM (IC50)) (Additional file 1:
Table S1A). KRO-105714 also had no cardiotoxicity
in the hERG potassium channel binding assay (IC50 >
10 μM) (Additional file 1: Table S1B).
Conclusions
Taken all together, this study demonstrates that KRO-
105714 acts as a dual inhibitor of SPC and S1P1 to effi-
ciently alleviate atopic dermatitis symptoms in vivo/
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in vitro through reduction of atopic dermatitis-related
chemokines and cytokines, angiogenesis and monocyte/
macrophage infiltration. Although further study is
needed to delineate the detailed signal pathways under-
lying the mode of action of KRO-105714, our results
strongly suggest that KRO-105714, a novel SPC and
S1P1 antagonist, is a potential therapeutic reagent with
low toxicity for atopic dermatitis.
Methods
Reagents
SPC was purchased from Matreya Inc. (Pleasant Gap, USA).
Lipopolysaccharide (LPS) and lectin from Phaseolus vulgaris
(PHA) were provided by Sigma Chemical Co. (St. Louis, MO,
USA). 1-Chloro-2,4-dinitrobenzene (DNCB), hydrocortisone
(HC), 12-O-tetradecanoylphorbol-13-acetate (TPA) and 4-
ethoxymethylene-2-phenyl-2-oxazolin-5-one (Oxazolone) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Other organic solvents and chemicals were of analytical grade
or complied with established standards for cell culture
experiments.
Cell culture and treatments
NIH3T3 (murine fibroblast) cells and HEK-293 (human
embryonic kidney) cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA)
and were maintained in DMEM (Gibco, BRL, Grand Is-
land, NY, USA), supplemented with 10% fetal bovine
serum (FBS) and 100 U/ml of penicillin-streptomycin, at
37 °C in 95% humidity and 5% CO2 atmosphere. Human
umbilical vein endothelial cells (HUVECs) were obtained
from Bio4You (Seoul, South Korea) and were maintained
in M199 (Gibco, BRL, Grand Island, NY), supplemented
with 20% FBS, basic fibroblast growth factor (bFGF)
(R&D Systems, Minneapolis, MN, USA), heparin, and
100 U/ml of penicillin-streptomycin at 37 °C in 95% hu-
midity and a 5% CO2 atmosphere. Raw 264.7 (mouse
macrophage) cells were obtained from the Korean Cell
Line Bank (KCLB, Seoul, South Korea) and were main-
tained in DMEM supplemented with 10% FBS and 100
U/ml of penicillin-streptomycin at 37 °C in 95% humid-
ity and a 5% CO2 atmosphere. Human peripheral blood
mononuclear cells (PBMCs) were isolated from the
blood of healthy individual donors by density-gradient
centrifugation through a Ficoll-Paque (GE Healthcare,
Chicago, IL, USA) gradient. The isolated human PBMCs
were cultured in RPMI1640 (Gibco, BRL, Grand Island,
NY, USA) and supplemented with 10% FBS and 100 U/
ml of penicillin-streptomycin.
Human peripheral blood
Peripheral blood from healthy donors was obtained from
the Red Cross Blood Center. We followed the guidelines
of the Red Cross, and all of the methods and protocols
used in this study with human peripheral blood were ap-
proved by the Institutional Review Board of the Red
Cross. Based on the Red Cross guidelines, informed con-
sent for study participation was obtained and donor in-
formation could not be provided. For preparation of
Peripheral blood mononuclear cells (PBMC), we isolated
PBMCs using ficoll-gradient centrifugation.
High-throughput screening (HTS) for SPC-induced cell
inhibition assay
NIH3T3 cells were seeded in 96-well plates at a density of
5 × 103 cells/well and stabilized overnight. The cells were
treated with test compounds at 25 nM, 50 nM, 0.25 μM,
and 2.5 μM for 30min, following which10 μM of SPC was
added. The cells were incubated for 24 h and 0.5 μCi/well
of [3H]-thymidine was loaded and further incubated for
24 h. The medium was aspirated, and the cells were thor-
oughly washed three times with PBS. Subsequently, a scin-
tillation cocktail was added, and the radioisotope that had
been incorporated into the cells was quantified using a
MicroBeta® TriLux (PerkinElmer, Waltham, MA, USA).
The automated screening assay was performed in an HTS
setup using Biomek FX and ORCA robot system (Beck-
man Coulter, Pasadena, CA, USA).
[35S]-GTPγS binding assay
HEK-293 cells stably expressing hS1P1 were homoge-
nized in an assay buffer (50 mM HEPES buffer, pH 7.5,
containing 100 mM NaCl, 5 mM MgCl2, 20 μM GDP)
and centrifuged at 45,000×g for 20 min at 4 °C. Aliquots
of pellets (5 μg) were pre-incubated with GTP-binding
buffer (50 mM HEPES buffer, pH 7.5, containing 100
mM NaCl, 5 mM MgCl2, 20 μM GDP, 0.1% BSA, 20 μg/
ml saponin) in the presence of the KRO-105714 (0.8 nM,
4 nM, 20 nM, 100 nM, 500 nM and 2.5 μM) for 30 min at
30 °C. [35S]-GTPγS (1200 Ci/mmol; 0.1 nM) was loaded
and incubated for 30 min at 30 °C. The reaction was then
terminated by rapid filtration under vacuum through a
UniFilter GF/C microplate, then scintillant is melted
onto the filter. The filter-bound radioactivity was
counted using a MicroBeta® Trilux. Nonspecific binding
(NSB) was determined in the presence of 30 μM GTPγS.
NSB was subtracted from each total binding of the indi-
cated concentration of KRO-105714 and the specific
binding (SB) was analyzed using four parameter nonlin-
ear regression with GraphPad Prism to yield inhibition
values (IC50).
Migration assay
Migration assays were performed in Transwell 96-well
chambers with 8-μm polycarbonate membrane filters
(Becton Dickinson Labware, Franklin Lakes, NJ). SPC
(10 μM), prepared in RPMI1640 with 1% FBS, was
placed in the lower well. HUVECs were harvested at a
Yoon et al. Journal of Inflammation           (2020) 17:20 Page 9 of 12
density of 2.5 × 105 cells/ml and treated with compounds
at 0.8 nM, 4 nM, 20 nM, 100 nM, 500 nM, and 2.5uM for
30min before seeding. The cell suspension (100 μl) was
loaded into the upper well. Cells were allowed to migrate
for 4 h in a humidified chamber at 37 °C with 5% CO2.
The cells were fixed and stained with hematoxylin and
eosin. Migration was quantified by counting the cells
that had attached to the lower surface of the filter using
an optical microscope at X200 magnification. Fifteen
fields were counted for each assay.
Tube formation assay
Matrigel (10 mg protein/ml, Clontech, MA, USA; 40 μl)
was pipetted into a 96-well culture plate and polymer-
ized for 1 h at 37 °C. HUVECs were harvested after
trypsin-EDTA treatment, re-suspended in M199 and
then plated onto a layer of Matrigel at a density of 2 ×
104 cells/well, followed by the addition of 10uM SPC in
the absence or presence of 2.5uM KRO-105714. After
the Matrigel cultures were incubated at 37 °C for 24 h,
the cultures were photographed (X40).
Elisa
Raw 264.7 cells and human PBMCs were seeded in 96-
well plates and pre-treated with of 1, 3, and 10 μM KRO-
105714. After incubating for 30min, raw 264.7 cells were
added with 10 μM SPC and PBMCs were added with
5 μg/ml PHA in the absence or presence of 10 μM SPC.
Supernatants were collected over a time course after the
addition of stimulators, and analyzed using ELISA kits in
accordance with the manufacturers’ instructions. ELISA
kits (MCP-1, IL-4 and IL-5) were purchased from BD Bio-
sciences (Franklin Lakes, NJ). We used normalization
method using standard curve with recombinant MCP-1,
IL-4 and IL-5 provided from vendor.
Animals
All the animals were purchased from Orient Bio (Seoul,
South Korea) and acclimated under specific pathogen-
free conditions in an animal facility for at least a week
before use. The mice were housed in a temperature
(23 ± 2 °C) and relative humidity (40–60%) controlled
room. Lighting was adjusted automatically at a cycle of
12 h light and 12 h dark. For sampling tissues from mice,
the animals were sacrificed by cervical dislocation. All
the animal protocols used in this study were approved
by the Korea Research Institute of Chemical Technology
(KRICT) Animal Care and Use Committee.
Mouse ear edema inflammation model using TPA
Dermatitis was induced by topical application of TPA
(2.5 μg/20 μl in acetone) to the ears of Crl:CD1 (ICR)
mice (8 weeks, male). Various concentrations (0.01,
0.05, 0.1, 0.5%) of KRO-105714 and 0.5% of
hydrocortisone (HC) were topically applied to the ear
twice: 15 min and 6 h after TPA treatment. The con-
trol group was treated with the vehicle alone (in acet-
one). Twenty-four hours after TPA application, the
mice were sacrificed by cervical dislocation, and sam-
ples were collected with a 6 mm diameter metal
punch and weighed. Tissue samples were assessed
biochemically with the neutrophil marker enzyme
myeloperoxidase (MPO) [29]. To measure MPO activ-
ity, homogenized tissue were freeze-thawed 3 times,
after which sonication was repeated. Suspensions were
then centrifuged at 40,000×g for 15 min and the
resulting supernatants assayed. One hundred micro-
liter of the ear tissue supernatants to be measured
was mixed with 2.9 ml of 50 mM phosphate buffer
(pH 6.0) containing 0.167 mg/ml o-dianisidine dihy-
drochloride and 0.0005% hydrogen peroxide. Chlorin-
ation activity of MPO was evaluated with 3′-(p-
aminophenyl) fluorescein (APF) and 3′-(p-hydroxy-
phenyl) fluorescein (HPF, both from Cayman Chemi-
cals, Ann Arbor, MI) 20 μl sample were combined
with 40 μl 2 μM H2O2 and 40 μl 20 μM APF or HPF
(in 1% methyl acetate). Fluorescence was measured at
499 nm excitation and 515 nm emission after 30 min.
HPF fluorescence values were subtracted from APF in
order to calculate MPO chlorination activity.
Mouse ear edema inflammation model using oxazolone
On study day 0 and 1, Balb/c mice (8 weeks, male) were
sensitized with aliquots of 50 μl of a 2% oxazolone solu-
tion epicutaneously on their shaved abdomens. On day 6,
the right ear of each mouse was challenged with 2% oxa-
zolone solution. Left ears were painted on both sides with
an ethanol/acetone mixture. The right ear of each mouse
was treated with the indicated concentration (0.05, 0.01,
0.1, 0.5%) of KRO-105714 and 0.5% HC twice (10 μl on
the front and 10 μl on the back) at both 0 h and 6 h after
the oxazolone-challenge. The control group was treated
with the vehicle alone (in acetone). After 24 h, the mice
were sacrificed, and ear samples were collected using a 6
mm diameter metal punch and weighed. Tissue samples
were assessed biochemically with the eosinophil marker
enzyme, eosinophil-peroxidase (EPO). To measure EPO
activity, aliquots of the ear tissue supernatants and 100 μl
of 50mM Tris-HCl buffer (pH 8.0) containing 0.1% Triton
X-100, 1 mM ο-phenylenediamine and 500 μM hydrogen
peroxide were incubated for 30min at room temperature.
The reaction was stopped by adding 50 μl of 2M sulfuric
acid and the absorbance at 490 nM was measured using a
microplate reader.
Evaluation of scratching behavior
To measure itch-related behavior induced by SPC,
KRO-105714 was administered to ICR mice (8 weeks,
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male) via oral administration of 1 and 10 mg/kg
KRO-105714 in 200 μl volume of 10% DMSO in PBS
per mouse using flexible oral gavage needle (Instech
Laboratories, Plymouth Meeting, PA, USA) 30 min be-
fore the SPC challenge. After SPC application (100
nM/site), bouts of scratching were counted for 30
min. Mouse scratching behavior was automatically de-
tected and objectively evaluated with a MicroAct ap-
paratus (Neuroscience Inc.). A small magnet (1 mm in
diameter, 3 mm long, coated with Teflon) was
inserted subcutaneously into both hind paws under
ether anesthesia before the start of the experiment.
Scratching of the rostral back and biting of the caudal
back were observed; scratching movements by the
hind paw were defined as a scratching bout, which
ended when the mouse either licked its hind paw or
placed its hind paw back on the floor. A series of one
or more biting movements was counted as one epi-
sode, which ended when the rat returned to the
straight-forward position.
DNCB-induced contact dermatitis
To induce dermatitis, NC/Nga mice (5 weeks, male)
were sensitized by painting 100 μl of 1% DNCB solution
(in acetone:olive oil = 4:1, v/v) onto the shaved back skin
(2 × 4 cm). After 4 days, mice were first immunized by
painting 150 μl of 0.2% DNCB solution three times per
7-day period for 3 weeks. Twenty-five days later, the ani-
mals were challenged with 150 μl of a mixture of 1% of
KRO-105714 or 1% of hydrocortisone (HC) with 0.2%
DNCB solution in polyethylene glycol:ethanol (7:3, v/v),
once daily for 4 days.
Flow cytometry
Human PBMCs were seeded in 96-well plates and pre-
treated with 1 and 10 μM of KRO-105714. After incubat-
ing for 30 min, these cells were treated with 10 μM SPC
and/or 5 μg/ml PHA. PBMCs were analyzed by flow cy-
tometry using 1 μg/ml of anti-CD45-APC (BioLegend,
San Diego, CA, USA), anti-ICAM-1 (BioLegend) and
anti-CD44 antibodies in phosphate-buffered saline (PBS)
plus 1% fetal bovine serum (FBS) on ice for 10 min. Cells
were then washed and analysed. Staining data were col-
lected using a FACSCanto II Cytometer (BD Biosci-
ences). To set the gates for defining positive and
negative cells at 5000 cells in multicolor staining, sam-
ples were stained with a mixture of all antibodies [50].
Statistical analysis
ANOVA multiple comparisons were performed to ana-
lysis differences among more two groups. Statistical ana-
lyses were performed using the Prism software package
(GraphPad Software, San Diego, CA, USA). Differences
with P values of 0.05 or less were considered significant.
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